Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

about

Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.

P2860

Q40083001-1FAF040B-A011-44C1-B1A4-FACD6650FCCE

P2860

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

Item

http://www.wikidata.org/entity/Q35826728

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

@ast

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

@en

type

Item

label

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

@ast

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

@en

prefLabel

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

@ast

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

@en

P1476

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

@en

P2093

Hisatoshi Shida

http://www.w3.org/2001/XMLSchema#string

Minoru Kidokoro

http://www.w3.org/2001/XMLSchema#string

P2860

Smallpox as a Biological Weapon

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Adverse events associated with smallpox vaccination in the United States, January-October 2003.

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

P304

755-771

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/VACCINES2040755

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26344890

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

4494248

http://www.w3.org/2001/XMLSchema#string

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

about

P2860

P2860

Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932